简
/
繁
/
EN
About Us
R&D
Products
News
Careers
Investors
Contact us
Investors
（02186.HK）
HK$
➚
%
Volume(M)
0thousand
Turnover(HK $)
0thousand
Data as of：
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact IR
Year
2022
2023
2024
2025
2026
26
2026-01
VOLUNTARY ANNOUNCEMENT TRANSFER OF SHARES BY CONTROLLING SHAREHOLDER
21
2026-01
VOLUNTARY ANNOUNCEMENT TRANSFER OF SHARES BY CONTROLLING SHAREHOLDER
14
2026-01
VOLUNTARY ANNOUNCEMENT FINANCE LEASE AGREEMENT
11
2026-01
ANNOUNCEMENT (1) UNUSUAL MOVEMENT IN TRADING VOLUME AND (2) DENOSUMAB (60MG) APPROVED FOR MARKETING IN BOLIVIA
06
2026-01
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2025
03
2025-12
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2025
26
2025-11
VOLUNTARY ANNOUNCEMENT BOYOUJING (AFLIBERCEPT INTRAVITREOUS INJECTION) APPROVED FOR MARKETING IN CHINA
07
2025-11
VOLUNTARY ANNOUNCEMENT MARKETING AUTHORISATION APPLICATIONS FOR THE COMPANY'S TWO DENOSUMAB INJECTIONS ACCEPTED IN THE UK
05
2025-11
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2025
30
2025-10
VOLUNTARY ANNOUNCEMENT THE ENROLLMENT FOR PHASE III TRIAL OF THE COMPANY'S NIVOLUMAB INJECTION HAS BEEN COMPLETED IN CHINA
1
2
3
4
5
Follow me
鲁公网安备37069102000284